The estimated Net Worth of Scott Hutton is at least $1.47 Миллион dollars as of 8 August 2024. Mr Hutton owns over 12,212 units of Biodesix Inc stock worth over $934,580 and over the last 4 years he sold BDSX stock worth over $0. In addition, he makes $531,882 as Pres и CEO & Director at Biodesix Inc.
Mr has made over 13 trades of the Biodesix Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 12,212 units of BDSX stock worth $21,859 on 8 August 2024.
The largest trade he's ever made was exercising 199,973 units of Biodesix Inc stock on 8 February 2024 worth over $357,952. On average, Mr trades about 25,709 units every 66 days since 2020. As of 8 August 2024 he still owns at least 522,112 units of Biodesix Inc stock.
You can see the complete history of Mr Hutton stock trades at the bottom of the page.
Scott Hutton is the Pres, CEO & Director at Biodesix Inc.
As the Pres и CEO & Director of Biodesix Inc, the total compensation of Mr Hutton at Biodesix Inc is $531,882. There are no executives at Biodesix Inc getting paid more.
Mr Hutton is 49, he's been the Pres и CEO & Director of Biodesix Inc since . There are 3 older and 2 younger executives at Biodesix Inc. The oldest executive at Biodesix Inc is Robert E. Cawthorn, 86, who is the Founder & Director Emeritus.
Scott's mailing address filed with the SEC is 919 WEST DILLON RD, , LOUISVILLE, CO, 80027.
Over the last 4 years, insiders at Biodesix Inc have traded over $0 worth of Biodesix Inc stock and bought 32,782,268 units worth $58,800,766 . The most active insiders traders include Jack W Schuler, Lawrence T. Jr Kennedy и Matthew Strobeck. On average, Biodesix Inc executives and independent directors trade stock every 12 days with the average trade being worth of $567,788. The most recent stock trade was executed by Chris Vazquez on 8 August 2024, trading 602 units of BDSX stock currently worth $1,078.
Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also offers GeneStrat ddPCR and VeriStrat tests, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to establish the patient's prognosis and help guide treatment decisions; and GeneStrat NGS (NGS) test, a 72-hour blood-based NGS test. In addition, the company, through its partnership with Bio-Rad Laboratories, Inc., provides Bio-Rad SARS-CoV-2 ddPCR, a COVID-19 Test under Biodesix WorkSafe testing program; and Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting a B-cell immune response to SARS-CoV-2 that indicate recent or prior infection. Further, it offers diagnostic and clinical research, as well as clinical trial testing services to biopharmaceutical companies; and discovers, develops, and commercializes companion diagnostics. The company was formerly known as Elston Technologies, Inc. Biodesix, Inc. was incorporated in 2005 and is headquartered in Boulder, Colorado.
Biodesix Inc executives and other stock owners filed with the SEC include: